Inhibitory Effect of Fulvic Acid Extracted from Canadian Sphagnum Peat on Chemical Mediator Release by RBL-2H3 and KU812 Cells
Key Findings
- FA extracted from Canadian Sphagnum peat (CP-FA) is not cytotoxic to RBL-2H3 cells at 0.001–10.0 µg/ml after 48h
- CP-FA inhibits β-hexosaminidase release from IgE-sensitized, antigen-stimulated RBL-2H3 cells at antigen-antibody binding stage (p<0.05 at 0.01–10.0 µg/ml)
- CP-FA inhibits β-hexosaminidase release at antibody-receptor binding stage (p<0.05 at 0.01–5.0 µg/ml)
- CP-FA decreases intracellular [Ca²⁺]i level in IgE-sensitized, antigen-stimulated RBL-2H3 cells
- CP-FA dose-dependently inhibits A23187+PMA- and compound 48/80-mediated histamine release from KU812 human basophilic cells at 1.0–10.0 µg/ml
- CP-FA molecular weight 780 Da; structural formula C₃₁H₃₆O₂₂N; purity 99.8%
- CP-FA characterized by FT-IR, ESR, ¹³C-NMR: contains aromatic rings, phenolic hydroxyl, ketone/quinone carbonyl, carboxyl, methoxyl groups
- Canadian Sphagnum peat contains 12.8% HA and 4.8% FA (dry weight)
- Antiallergic mechanism attributed to calcium ion chelating activity and free radical scavenging activity of FA
- FA designated as food by Japanese Ministry of Health and Welfare in June 2005
Rigorous in-vitro study demonstrating the antiallergic properties of fulvic acid extracted from Canadian Sphagnum peat. CP-FA inhibits mast cell degranulation at two stages: antigen-antibody binding and antibody-receptor binding. The mechanism involves decreased intracellular calcium levels and inhibition of histamine release from both rat (RBL-2H3) and human (KU812) basophilic cells. The antiallergic effect is attributed to the chemical composition of FA — aromatic rings with phenolic hydroxyl, quinone carbonyl, and methoxyl functional groups — which shares structural similarities with flavonoid antiallergic compounds like quercetin and luteolin. CP-FA from Sphagnum peat showed stronger antiallergic activity than FA from weathered coal, suggesting peat origin matters.
Where this source is used on this site
Each page below cites this paper as evidence for a specific claim. The note shows what the page draws from it.
CP-FA inhibits β-hexosaminidase and histamine release from mast/basophilic cells
CP-FA inhibits β-hexosaminidase and histamine release from mast/basophilic cells
CP-FA inhibits β-hexosaminidase release at antigen-antibody and antibody-receptor binding stages (p<0.05); inhibits histamine release from KU812 human basophilic cells; decreases intracellular [Ca²⁺]i
FA inhibits histamine release from mast/basophilic cells — histamine is primary itch mediator in atopic dermatitis
FA inhibits histamine release — histamine mediates itch in scalp conditions